27 min listen
Declining R&D Productivity Continues to Plague Big Pharma
FromThe Bio Report
ratings:
Length:
19 minutes
Released:
Dec 17, 2015
Format:
Podcast episode
Description
Despite a record number of new drug approvals this year, the return on R&D investment for the largest pharmaceutical companies continues to fall, according to a new report from the Deloitte Centre for Health Solutions and Deloitte’s R&D services group. In fact, the report finds R&D returns for this group of companies have fallen to their lowest point since Deloitte began tracking them in 2010. We spoke to Neil Lesser, principal with Deloitte Consulting in the Life Sciences strategy practice and a leader in the Research & Development strategy practice, about the report, the pressures on the industry that are hurting returns, and what R&D strategies companies can pursue that might reverse the trend.
Released:
Dec 17, 2015
Format:
Podcast episode
Titles in the series (100)
Remembering Industry Pioneer Ron Cape by The Bio Report